[MCK] McKesson Thesis 2026: GLP-1 Distribution Volume Anchors Pharmaceutical Cycle
Key Takeaways
- FY2025 revenue ~$355-365B (+8-12% YoY) with adj. EPS ~$32-34 — McKesson Corporation is the largest US pharmaceutical distribution + healthcare services company. Fiscal year ends March. FY2025 reflects continued pharmaceutical distribution volume growth + selected GLP-1 weight-loss drug tailwind (Ozempic + Wegovy + Mounjaro + Zepbound distribution) + selected pricing modest + selected operational discipline + selected opioid litigation cost continuation.
- 4 segments: US Pharmaceutical ~88% + Prescription Technology Solutions ~3% + Medical-Surgical Solutions ~3% + International ~6% — US Pharmaceutical dominant economic engine including drug distribution to pharmacies + hospitals + selected; Prescription Technology Solutions includes pharmacy software + selected; Medical-Surgical Solutions includes selected; International primarily Canada Rexall + selected European operations. Selected pharmaceutical distribution scale moat extremely difficult to replicate.
- CEO Brian Tyler since April 1, 2019 — Tyler succeeded John Hammergren (CEO 1999-2019; transitioned). Tyler background: ex-McKesson President + selected operational background; ~25-year McKesson career. Tyler's tenure has executed: continued pharmaceutical distribution scale growth + selected operational excellence + opioid litigation $7.4B settlement 2022 (selected continuing) + selected international portfolio optimization (selected European operations divestitures + selected) + capital return acceleration. Capital return: dividend $2.48-2.62/share annual + buybacks $3-4B; net debt ~$3-5B; investment-grade A3/BBB+ credit rating.
- FY2026 thesis: GLP-1 distribution volume continued + selected operational scale + capital return + selected international focus — GLP-1 weight-loss drug class continues selected unprecedented prescription volume growth driving McKesson distribution; pharmaceutical distribution scale moat sustained; capital return acceleration. Key risks: drug pricing reform (selected Inflation Reduction Act + selected administrative actions), opioid litigation continuing (selected ongoing claims beyond 2022 settlement), generic substitution (selected pricing pressure on selected categories).
Company Background
McKesson Corporation (NYSE: MCK), founded 1833 by John McKesson + Charles Olcott as small drug import business in New York City (selected oldest US pharmaceutical distributor; multi-decade evolution into selected modern pharmaceutical distribution + healthcare services), is the largest US pharmaceutical distribution + healthcare services company. Headquartered in Irving, Texas (relocated from San Francisco 2018), McKesson operates as one of the "Big 3" US pharmaceutical distributors (alongside Cencora ABC + Cardinal Health) selected dominating US drug distribution. McKesson's competitive moat rests on three structural advantages: (1) selected pharmaceutical distribution scale — selected distribution to ~80% of US hospitals + selected pharmacies + selected institutional customers creates selected scale economies + selected logistics moat extremely difficult to replicate; (2) selected manufacturer relationships — multi-decade selected pharmaceutical manufacturer relationships + selected pricing dynamics + selected; (3) selected technology + selected operational efficiency — selected pharmaceutical supply chain technology + selected automated distribution + selected.
CEO Brian Tyler took CEO role April 1, 2019 (succeeded John Hammergren CEO 1999-2019; Hammergren transitioned amid selected opioid litigation criticism). Tyler's background:
- McKesson President + selected operational roles
- ~25-year McKesson career
Tyler's tenure has executed:
- 2019-2021 Initial CEO Phase: selected operational excellence + selected opioid litigation management
- 2022 Opioid Settlement: $7.4B settlement (Big 3 pharmaceutical distributors selected combined ~$26B opioid settlement; multi-year payments through ~2040)
- 2022-2023 International Portfolio Optimization: selected European operations divestitures (selected German + selected UK operations sold)
- 2023-2025 GLP-1 Volume Surge: GLP-1 weight-loss drug class (Ozempic + Wegovy + Mounjaro + Zepbound) creating selected unprecedented pharmaceutical distribution volume tailwind for McKesson + Big 3
- 2024-2025 Continued Discipline: continued operational excellence + capital return acceleration
Tyler's strategic positioning emphasizes:
- US Pharmaceutical scale + operational efficiency
- GLP-1 + selected specialty pharmaceutical volume capture
- Selected international focus (Canada + selected; European exits substantially complete)
- Capital return acceleration (dividend + buybacks)
- Selected opioid litigation management
Business Structure
McKesson reports operations across 4 segments:
1. US Pharmaceutical — ~$315B FY2025 (~88% of revenue):
- Drug distribution to pharmacies (CVS + Walgreens + Walmart Pharmacy + selected; ~50K+ pharmacy customer base)
- Drug distribution to hospitals (~80% of US hospitals served; selected)
- Specialty pharmaceutical distribution (selected oncology + selected biologics + selected)
- GLP-1 weight-loss drugs (Ozempic + Wegovy + Mounjaro + Zepbound) creating selected unprecedented volume
- Operating margin ~1.0-1.4% (very thin pharmaceutical distribution margin; offset by selected enormous volume)
2. Prescription Technology Solutions — ~$10-12B FY2025 (~3% of revenue):
- Pharmacy software + selected technology services
- Selected prescription processing + selected
- Operating margin ~10-15% (higher-margin)
3. Medical-Surgical Solutions — ~$10-12B FY2025 (~3% of revenue):
- Medical-surgical product distribution
- Selected medical equipment + selected
- Operating margin ~5-8%
4. International — ~$20-22B FY2025 (~6% of revenue):
- Canada (Rexall pharmacy + selected)
- Selected smaller European operations
- Operating margin ~2-4%
Customer Mix:
- Pharmacies (chains + independent): ~50%
- Hospitals + health systems: ~25%
- Specialty pharmacy + selected: ~15%
- Other (mail order + selected): ~10%
Key Core Metrics
Financial Performance Summary
| Metric | FY2022 | FY2023 | FY2024 | FY2025E |
|---|---|---|---|---|
| Revenue ($B) | 263.7 | 276.7 | 309.0 | 355-365 |
| Adj. EPS ($) | 23.69 | 26.13 | 28.50 | 32-34 |
| Operating margin (%) | 1.0 | 1.1 | 1.2 | 1.3-1.5 |
| FCF ($B) | 4.0 | 4.5 | 5.0 | 5-6 |
| Net debt ($B) | 5 | 4 | 4 | 3-5 |
| Diluted shares (M) | 145 | 137 | 132 | 129 |
| Annual dividend/share ($) | 1.92 | 2.16 | 2.40 | 2.48-2.62 |
Capital Return Framework (FY2025)
| Component | Annual ($B) | Per Share ($) |
|---|---|---|
| Dividend | ~0.32 | 2.48-2.62 |
| Buybacks | ~3-4 | (~3-5%/yr share count reduction) |
| Total capital return | ~3.32-4.32 |
Market Evaluation
McKesson Corporation trades at ~17-20x forward earnings with ~0.5% dividend yield, reflecting pharmaceutical distribution valuation framework where investors price near-term GLP-1 volume + scale + opioid resolution + capital return into multiple. Bull case: GLP-1 distribution volume continues selected unprecedented growth + pharmaceutical distribution scale moat sustained + capital return acceleration; opioid litigation manageable with $7.4B settlement substantially completed. Bear case: drug pricing reform (selected Inflation Reduction Act + administrative actions affecting drug economics + selected distribution margins), opioid litigation continuing (selected ongoing claims beyond 2022 settlement), generic substitution (selected pricing pressure).
Compared to peers: MCK vs Cencora (formerly AmerisourceBergen ABC, similar Big 3 pharmaceutical distributor ~$285B revenue); MCK vs Cardinal Health (CAH, third Big 3 distributor ~$220B revenue); MCK vs Walgreens Boots Alliance (WBA, retail pharmacy + selected) — different model; MCK vs CVS Health (CVS, integrated retail pharmacy + Aetna insurance + selected) — different model; MCK vs Henry Schein (HSIC, smaller medical/dental distribution) — different scale. McKesson's selected scale + selected manufacturer relationships + selected automated distribution create structural advantages in selected high-volume low-margin pharmaceutical distribution.
GLP-1 Volume + Distribution Scale + Capital Return
The FY2026 thesis for McKesson centers on GLP-1 distribution volume continued growth + pharmaceutical distribution scale moat + capital return acceleration through selected pharmaceutical cycle.
GLP-1 Distribution Volume Tailwind:
- GLP-1 weight-loss drug class (Ozempic + Wegovy + Mounjaro + Zepbound + selected) creating selected unprecedented prescription volume growth
- Industry GLP-1 sales: selected $30B+ in 2024 → $50B+ in 2026 → $100B+ by 2030 (selected projected)
- McKesson distributes selected major share of US GLP-1 prescription volumes
- FY2024-2025 US Pharmaceutical revenue +12-15% YoY partly driven by GLP-1
- FY2026 expected: continued GLP-1 volume growth driving distribution revenue
- Selected manufacturer relationships (Eli Lilly + Novo Nordisk) provide selected distribution dynamics
Pharmaceutical Distribution Scale Moat:
- Selected ~80% of US hospitals served
- ~50K+ pharmacy customer base
- Selected automated distribution + selected logistics
- Multi-decade selected manufacturer relationships
- Selected scale economies in selected high-volume low-margin business
Opioid Litigation Status:
- $7.4B settlement 2022 (Big 3 pharmaceutical distributors combined ~$26B; McKesson share ~$7.4B)
- Multi-year payments through
2040 ($0.5-0.8B annual) - Selected continuing opioid claims (selected smaller; selected manageable)
- FY2025-2026 expected: selected manageable opioid cash flow impact
Capital Return Acceleration:
- Dividend $2.48-2.62/share FY2025 (continuing increases ~5-10%/yr post-Hammergren era)
- Buybacks $3-4B FY2025 (~3-5%/yr share count reduction; share count 145M FY2022 → 129M FY2025E ~11% reduction)
- Total capital return $3.32-4.32B
- Net debt $3-5B (modest; selected cash-rich)
- Investment-grade A3/BBB+
FY2026 Outlook:
- Revenue toward $370-385B FY2026 (+5-8% on GLP-1 + selected pricing)
- Adj. EPS toward $34-36 (+5-10%)
- Operating margin sustained 1.3-1.5%
- FCF $5-6B
- Capital return $3.5-4.5B
- Dividend toward $2.65-2.80/share
- FY2027 outlook: revenue $385-405B, adj. EPS $36-39, capital return $3.8-5B
Key Risks:
- Drug pricing reform (Inflation Reduction Act drug price negotiation + selected administrative actions affecting drug economics + selected distribution margins; selected ongoing legal challenges)
- Opioid litigation continuing (selected ongoing claims beyond 2022 settlement; selected new claims selectively)
- Generic substitution (selected pricing pressure on selected categories; selected biosimilar substitution)
- Selected technology disruption (selected direct-to-consumer + selected mail-order pharmacy bypass)
- Selected commodity input cost inflation
- Selected currency volatility (international ~6% of revenue)
- Selected manufacturer relationship dynamics (selected pricing + selected distribution terms)
FY2026 Watch Items:
- GLP-1 prescription volume growth (target +20-30%/yr industry)
- Adj. EPS growth (target +5-10%)
- Capital return execution ($3.5-4.5B target)
- Operating margin trajectory (target 1.3-1.5%)
- Dividend trajectory (5-10%/yr increases)
- Drug pricing reform regulatory developments
- Opioid litigation new claims
McKesson Corporation's FY2026 thesis is GLP-1 distribution volume + pharmaceutical distribution scale moat + capital return acceleration. Validation: GLP-1 volume continues + scale moat sustained + capital return delivered + dividend growing = thesis intact. Failure mode: drug pricing reform severe + opioid litigation escalation + generic substitution acceleration + GLP-1 volume disruption = pharmaceutical distribution cycle compression McKesson cannot fully insulate against despite scale advantages.